A retrospective, multicenter study of the efficacy of lapatinib plus trastuzumab in HER2-positive metastatic breast cancer patients previously treated with trastuzumab, lapatinib, or both: the Trastyvere study.

Fecha de publicación: Fecha Ahead of Print:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Gavilá J
  • De La Haba J
  • Bermejo B
  • Rodríguez-Lescure Á
  • Antón A
  • Ciruelos E
  • Brunet J
  • Muñoz-Couselo E
  • Santisteban M
  • Rodríguez Sánchez CA
  • Sánchez Rovira P
  • García Sáenz JÁ
  • Ruiz-Borrego M
  • Guerrero-Zotano AL
  • Huerta M
  • Cotes-Sanchís A
  • Lao Romera J
  • Aguirre E
  • Cortés J
  • Llombart-Cussac A

Grupos

Abstract

To evaluate the efficacy and safety of lapatinib (L) and trastuzumab (T) combination in HER2-positive metastatic breast cancer (MBC) patients previously treated with T and/or L.

Datos de la publicación

ISSN/ISSNe:
1699-048X, 1699-3055

Clinical & Translational Oncology  SPRINGER INT PUBL AG

Tipo:
Article
Páginas:
420-428
PubMed:
31203575
Factor de Impacto:
0,902 SCImago ℠
Cuartil:
Q2 SCImago ℠

Citas Recibidas en Web of Science: 8

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • Dual HER2 blockade, Human epidermal growth factor receptor 2 positive, Lapatinib, Metastatic breast cancer, Trastuzumab, Tyrosine kinase inhibitor

Campos de Estudio

Compartir